- Home
- JAKK vs PLX Comparison
JAKK vs PLX Comparison
Compare JAKK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAKK | PLX |
|---|---|---|
| Founded | 1995 | 1993 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.9M | 230.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JAKK | PLX |
|---|---|---|
| Price | $17.59 | $2.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $36.67 | $12.00 |
| AVG Volume (30 Days) | 109.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | $6.54 | $16.65 |
| P/E Ratio | ★ $33.07 | $43.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.87 | $1.32 |
| 52 Week High | $35.79 | $3.10 |
Technical Indicators
Market Signals| Indicator | JAKK | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 72.63 |
| Support Level | $17.23 | $2.81 |
| Resistance Level | $18.49 | $3.03 |
| Average True Range (ATR) | 0.63 | 0.17 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 22.73 | 93.00 |
Price Performance
Historical ComparisonAbout JAKK JAKKS Pacific Inc.
Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells and distributes toys and related kid-targeted consumer products, inclusive of kids indoor and outdoor furniture, costumes and various product lines in the sporting goods and home furnishings space. Its products offering include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: (i) Toys/Consumer Products and (ii) Costumes.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.